Objectives: Interleukin-6 (IL-6) is critical for the development of non-small-cell lung cancer (NSCLC). Recently, we identified T-cell immunoglobulin domain and mucin domain 4 (TIM-4) as a new pro-growth player in NSCLC progression. However, the role of TIM-4 in IL-6-promoted NSCLC migration, invasion and epithelial-to-mesenchymal transition (EMT) remains unclear. Materials and Methods: Expressions of TIM-4 and IL-6 were both evaluated by immunohistochemical staining in NSCLC tissues. Real-time quantitative PCR (qPCR), Western blot, flow cytometry and RT-PCR were performed to detect TIM-4 expression in NSCLC cells with IL-6 stimulation. The roles of TIM-4 in IL-6 promoting migration and invasion of NSCLC were detected by transwell assay. EMT-related markers were analysed by qPCR and Western blot in vitro, and metastasis was evaluated in BALB/c nude mice using lung cancer metastasis mouse model in vivo. Results: High IL-6 expression was identified as an independent predictive factor for TIM-4 expression in NSCLC tissues. NSCLC patients with TIM-4 and IL-6 double high expression showed the worst prognosis. IL-6 promoted TIM-4 expression in NSCLC cells depending on NF-κB signal pathway. Both TIM-4 and IL-6 promoted migration, invasion and EMT of NSCLC cells. Interestingly, TIM-4 knockdown reversed the role of IL-6 in NSCLC and IL-6 promoted metastasis of NSCLC by up-regulating TIM-4 via NF-κB. Conclusions: TIM-4 involves in IL-6 promoted migration, invasion and EMT of NSCLC. S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section.
| INTRODUC TI ON
Non-small cell lung cancer (NSCLC) is one of the malignant tumours with the fastest increase in mortality despite the implementation of novel targeted therapies and chemotherapeutic regimes. 1, 2 Metastasis is responsible for the poor prognosis of NSCLC. 3, 4 Epithelial-mesenchymal transition (EMT), as a key regulator of metastasis, involves a series of phenotypic and behavioural changes, which contributes to the transformation of early tumours into invasive malignant tumours. 5, 6 EMT has been verified to be responsible for the development of NSCLC resistance to anti-cancer agents. [7] [8] [9] Therefore, early identification of novel prognostic molecular markers related to NSCLC metastasis and EMT is urgently required.
Our previous studies showed that T-cell immunoglobulin domain and mucin domain 4 (TIM-4), closely related to poor NSCLC prognosis, could promote the growth, proliferation and cell cycle progress of NSCLC cell lines through the interaction of its RGD motif. 10 However, the role of TIM-4 in NSCLC metastasis and EMT has not been reported. Moreover, TIM-4 levels in NSCLC tissues are significantly elevated, while the expression levels in various lung cancer cell lines are relatively low, 10 and the relevant mechanism is still unclear.
Interleukin-6 (IL-6) is an important cytokine for EMT and tumour metastasis of NSCLC. [11] [12] [13] The increase of IL-6 can cause the resistance to molecular targeted therapy in lung cancer, [14] [15] [16] and circulating IL-6 level may be a prognostic marker for patients with NSCLC. 17 Moreover, a humanized anti-IL-6 antibody (ALD518) has been used to treat NSCLC. 18 Our previous studies showed that IL-6 could induce TIM-4 expression in vitro. 10 Here, we investigated the exact role of TIM-4 in IL-6-induced NSCLC migration, invasion and EMT.
| MATERIAL S AND ME THODS

| Animals
Pathogen-free BALB/c nude mice (5-6 weeks old, male) bought from Vital River Laboratory Animal Technology Co., Ltd were randomly assigned to experimental groups and housed in home cages with an alternating 12 hours light and 12 hours dark cycle, water available, in the Animal Center of Shandong University under specific pathogen-free conditions. All animal experiments were performed with the approval of the Committee on the Ethics and use of Animal Experiments of Shandong University.
| Human samples
Non-small-cell lung cancer tissues samples were collected from 106 patients who had undergone surgery at Zhoushan Hospital (Zhejiang, China) from January 1 in 2011 to January 1 in 2014, without receiving preoperative chemo-or radiotherapy. The patients' age, gender, smoking history, carcinoembryonic antigen (CEA), tumour size, histology type, pleural invasion, lymph node metastasis, stage, and grade were determined by a reviewer according to the medical records. Each tumour sample was classified according to the 8th edition tumour-nodemetastasis (TNM) classification of lung cancer. Follow-up duration was determined from the date of surgical treatment until the death. The study was approved by the ethics committee of Zhoushan Hospital.
| In vivo lung cancer metastasis test
Migratory ability was determined with lung cancer metastasis test in BALB/c nude mice. Briefly, A549 cells were transfected with LV-NC-Luciferase (LV-NC) or LV-shTIM-4-Luciferase (LV-shTIM-4), respectively. Stable cell lines with TIM-4 knockdown or control were obtained by a high concentration of puromycin selection (12 μg/ mL) for 2 weeks, and subsequently, stable clones were maintained in culture with a low concentration of puromycin (1 μg/mL) for tumour bearing in BALB/c nude mice. Then, a tail-vein injection model administration intraperitoneally (n = 3). And the dose of IL-6 (dissolved in PBS) was 2.5 μg/kg once daily at 10 o'clock in the morning for the first 2 weeks, then 5 μg/kg once every 3 days throughout the next 4 weeks. After 6 weeks, mice were monitored using the IVIS Spectrum In Vivo Imaging System (PerkinElmer) of Advanced Medical Research Institute, Shandong University. Mice were intraperitoneally injected with 200 μL of D-luciferin (150 mg/kg body weight, PerkinElmer) and anesthetized with isoflurane gas after 5 minutes. One minute later, mice entered the state of general anaesthesia, and then, they were transferred into the cage of the in vivo imaging system. The chest and abdomen of mice were completely 
| Statistical analysis
GraphPad Prism 6.0 software was used for data analysis. Log-rank test was utilized to compare the survival for different groups. A logistic regression model was applied to investigate the independent predictive factors responsible for TIM-4 expression. Additionally, the correlation between TIM-4 and IL-6 was analysed by Spearman's rank correlation. P-values of <0.05 were considered as statistically significant. Other quantitative values were presented as the mean ± SD. Represent data were from at least triple or duplicate independent experiments. The differences in mean values between two groups were analysed by the Student's t test. *P < .05, **P < .01, ***P < .001, ****P < .0001, ns: not significant.
Additional supporting information of MATERIALS AND
METHODS could be found in the Appendix S1.
| RE SULTS
| High expression of TIM-4 was positively correlated with IL-6 in NSCLC, which indicated poor prognosis
Previously, we found that TIM-4 was highly expressed in cancer tissues of NSCLC. 10 Here, we further investigated the predictive factors for TIM-4 expression in clinical samples of NSCLC. Multivariate logistic regression analysis showed that tumour size (>3 cm) (OR, 2.574; 95% CI, 1.646-4.026; P = .032), lymph node metastasis (OR, 2.011; 95% CI, 1.472-3.744; P = .027) and high IL-6 expression (OR, 2.951; 95% CI, 1.082-6.085; P = .038) were independent predictive factors for TIM-4 expression (Table 1 ). Subsequently, the correlation between TIM-4 and IL-6 were analysed separately, and it was shown that TIM-4 expression was positively correlated with IL-6 expression in NSCLC ( Table 2 , r = .489, P = .021). Representative stained fields on histopathological slides for TIM-4 and IL-6 were displayed in Figure 1A . Additionally, the combination of TIM-4 and/or IL-6 expressions was used to explore the relationships with prognosis. As shown in Figure 1B , patients with high TIM-4 and IL-6 expression showed the worst prognosis, while patients with TIM-4 and IL-6 double low appeared the best prognosis (P = .0282). These results suggested that TIM-4 might be involved in the process of IL-6 promoting the development of NSCLC.
| IL-6 promoted TIM-4 expression in NSCLC cell lines via NF-κB pathway
To verify that IL-6 abundant in tumour microenvironment can induce high expression of TIM-4, lung cancer cell lines (A549 and H1975) were treated with 50 ng/mL IL-6 for the indicated time points (0, Figure   S1A ). Subsequently, 50 ng/mL IL-6 was used to stimulate lung cancer cells for 24 hours. Above all, the results showed that TIM-4 expression in lung cancer cell lines was up-regulated after IL-6 stimulation.
It was reported that TIM-4 inhibited cytokine production via NF-κB signalling pathway 19 and had no effect on STAT3 phosphorylation, 20 while IL-6 could increase the activation of NF-κB 16 and STAT3 signalling pathway. 21 We then tested the changes of these signal molecules in IL-6-induced up-regulation of TIM-4 in lung cancer cells with NF-κB inhibitor or STAT3 inhibitor, respectively. The results revealed that IL-6 could increase the phosphorylation of p65 To verify whether IL-6 promotes TIM-4 promoter activity through transcription factor NF-κB, we successfully constructed TIM-4 promoter (−1247 to +300 bp) reporter plasmid (pGL3-Basic-hTIM-4-full fragment). Functional analysis of dual-luciferase assay system both in A549 and H1975 cells showed that IL-6 could enhance TIM-4 promoter activity ( Figure 2E ). Then, we predicted and Figure S1B ). In accordance with the above prediction results, the effect of IL-6 on promoting TIM-4 promoter activity was attenuated after the addition of a specific inhibitor of NF-κB ( Figure 2E ).
| TIM-4 overexpression promoted metastasis of NSCLC cells
Interestingly, we found that cell morphology of A549 and H1975 cells overexpressed with pcDNA3-hTIM-4-HA (pTIM-4) were more spindle-like shape or fibroblast-like than control cells ( Figure S2A,B) . Figure 3A,B) . These data suggested that TIM-4 overexpression indeed significantly promotes EMT process of lung cancer cells.
Additionally, in the EMT process, tumour cells tend to appear much stronger abilities in migration and invasion, so we tested the effects of TIM-4 on the migratory and invasive capabilities of 
| TIM-4 increased IL-6 production
To detect whether TIM-4 knockdown affects the expression of IL-6, we detected the attenuated IL-6 expression in transcriptional level by RT-PCR after interfering TIM-4 (LV-shTIM-4-GFP) in A549 cells ( Figure S4A ). We then tested the changes of signal molecules NF-κB and STAT3 in A549 cells overexpressed TIM-4 with NF-κB inhibitor or STAT3 inhibitor, respectively. The results revealed that TIM-4 promoted the phosphorylation of STAT3 and secretion of IL-6 in A549 cells, but not phosphorylation of P65 ( Figure S4B ).
However, TIM-4-induced up-regulation of IL-6 in A549 cells was slightly decreased in STAT3 inhibitor treatment group, but no change was found in NF-κB inhibitor group ( Figure S4B ). Above all, TIM-4 could also increase IL-6 production in lung cancer cells, which might form a positive feedback loop in IL-6 involved lung cancers.
| IL-6 promoted metastasis of NSCLC by upregulating TIM-4 via NF-κB in vitro
Consistent with the report, 22 we found that IL-6 promoted migration and EMT of lung cancer cells ( Figure S5A 
| TIM-4 knockdown inhibited IL-6-enhancing migration and invasion in lung cancer cells in vivo
The lung metastasis mice model was established to investigate Figure 5C ). Mice were sacrificed after 7 weeks of tumour bearing, and lung tissues were photographed.
There were the most tumour nodules in IL-6 administration group, and few tumour nodules were found in shTIM-4 group ( Figure 5D ). In order to observe tumour nodules more intuitively, we performed HE staining with lung tissues. Metastatic nodules were counted in imaging scans, and the results showed that compared with NC group, mice in shTIM-4 group showed decreased lung metastasis nodes, and mice in IL-6 administration group showed a large number of lung metastasis nodules, while in shTIM-4 plus IL-6 group, lung metastasis nodules were increased slightly ( Figure 5E ). Though we did not inhibit NF-κB signalling in vivo, we detected the elevated expression of pP65 and TIM-4 in lung tissues from LV-NC plus IL-6 group by Western blot (Figure S6 Figure 6 ).
| D ISCUSS I ON
This is the first study to investigate the role of TIM-4 in IL-6inducing migration, invasion and EMT of NSCLC cells. We proved that high IL-6 expression was an independent predictive factor for TIM-4 expression in human NSCLC tissues. Importantly, our study showed that IL- TIM-4 was initially found to be expressed only in antigen-presenting cells. Our previous studies showed that LPS, IFN-γ and ConA could enhance TIM-4 expression in macrophages. 23, 24 It was also reported that damage-associated molecular patterns released from chemotherapy-damaged tumour cells induced TIM-4 expression on tumour-associated macrophages and dendritic cells. 25 Recent studies have shown that TIM-4 is overexpressed in several tumours, 26, 27 which is related with the worse prognosis of lung cancer as PD-L1, which further aggravated the tumour development. [28] [29] [30] Therefore, it was worth exploring whether TIM-4 expression was regulated by IL-6 in NSCLC cells. In clinical samples with NSCLC, we found that IL-6 was an independent predictor of TIM-4 expression, and patients with TIM-4 and IL-6 double high expression showed the worst prognosis. Importantly, we found that IL-6 indeed increased TIM-4 expression in lung cancer cell lines.
Next, we further examined the mechanism by which IL-6 induced the expression of TIM-4. As we know, NF-κB is considered to be a central mediator of immune and inflammatory response, and IL-6 could increase the activation of NF-κB signalling pathway. [31] [32] [33] In addition, Wang et al 32 demonstrated that IL-6-induced intercellular adhesion molecule expression required NF-κB activation, while our previous study showed that TIM-4, acting as an adhesion molecule, bound to integrin to promote lung cancer growth. 10 As expected, our study found that IL-6 promoted TIM-4 expression in NSCLC cell lines via NF-κB pathway. In addition to NF-κB, STAT3 is another key factor in IL-6 signalling pathway, 34, 35 and it has been documented that IL-6 promoted lung cancer development and progression by activating STAT3. 36, 37 Another study found that IL-6 could induce immunosuppressive factor PD-L1 expression on peripheral myeloid cells through STAT3-dependent mechanism. 38 However, we did not observe the significant change of IL-6-inducing elevated TIM-4 expression in STAT3 inhibitor treatment group. It is interesting that TIM-4 overexpression promoted IL-6 production in lung cancer cells.
Taken together, our data revealed the mechanism of up-regulation of TIM-4 expression in lung cancer cells, which would provide a new target for regulating TIM-4 expression in tumour microenvironment.
Previously, we identified for the first time that TIM-4 expression was augmented in NSCLC cancer tissues and was negatively correlated with the prognosis of patients. 10 Also, it was shown that TIM-4 overexpression promoted lung cancer cell growth and proliferation both in vitro and in vivo. 10 was functioned as a tumour promoter in lung cancer. However, the molecular mechanism of TIM-4 regulating EMT and then regulating metastasis requires to be further investigated.
Our published data reported that TIM-4 could regulate cytokine production in macrophages. 24 Whether TIM-4 affects the expression of IL-6 in lung cancer cells remains to be clarified. To this end, we tested IL-6 levels in TIM-4 knockdown A549 cells and found that IL-6 expression was down-regulated. Both NF-κB and STAT3 pathways regulate IL-6 production, which plays an important role in the development and prognosis of lung cancer. We demonstrated that TIM-4 overexpression could lead to STAT3 activation in lung cancer cells, while TIM-4 did not induce phosphorylation of NF-κB. Therefore, we concluded that TIM-4 increased IL-6 production in lung cancer cells. However, the related mechanism requires further investiga- University, for their support.
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